Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts
Our results demonstrate that concurrent upregulation of both glycolysis and oxidative phosphorylation pathways occurs in vivo in PDAC PDXs following gemcitabine treatment and that pathogenic TP53 status had association with gemcitabine resistance in these models. Our findings may elucidate the molecular basis for gemcitabine resistance and provide insights for effective drug combination in PDAC chemotherapy.
Authors
- Mariam M. Konaté (ORCID: https://orcid.org/0000-0003-1708-1348)
- P. Mickey Williams
- Rini Pauly (ORCID: https://orcid.org/0000-0002-0664-9308)
- Lisa M. McShane (ORCID: https://orcid.org/0000-0001-8195-3206)
- Julia Krushkal (ORCID: https://orcid.org/0000-0002-0950-0621)
- Yuri Kotliarov (ORCID: https://orcid.org/0000-0002-6558-8883)
- Yingdong Zhao (ORCID: https://orcid.org/0000-0002-8514-0293)
- Alida Palmisano (ORCID: https://orcid.org/0000-0002-1859-3719)
- Li Chen (ORCID: https://orcid.org/0000-0001-9303-4047)
- Ming-Chung Li
- Qian Xie
Institutions
- Leidos (United States) (US)
- National Institutes of Health (US)
- General Dynamics (United States) (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1186/s12967-024-05528-6
- Citations
- 10
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.83